Who
Gilbert Lynn Marks
Director
Company insider
Files Form 4 as: Director, AN2 Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 12 May 2022
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,283 at $0.00 | filing |
| 10 Jul 2026filed 10 Jul 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,789 at $0.00 | filing |
| 10 Jul 2026filed 10 Jul 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,789 at $0.00 | filing |
| 10 Apr 2026filed 10 Apr 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,775 at $0.00 | filing |
| 10 Apr 2026filed 10 Apr 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,775 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,665 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,665 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,665 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,665 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,560 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.